Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04221-0
Abstract: The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is… read more here.
Keywords: bispecific cell; cell malignancies; immuno oncology; cell engager ... See more keywords
Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats
Sign Up to like & getrecommendations! Published in 2020 at "Current Medical Science"
DOI: 10.1007/s11596-020-2143-y
Abstract: Selecting an ideal molecular format from diverse structures is a major challenge in developing a bispecific antibody (BsAb). To choose an ideal format of anti-CD3 × anti-transferrin receptor (TfR) bispecific antibodies for clinical application, we… read more here.
Keywords: chain; bispecific cell; anti transferrin; cell engager ... See more keywords
Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2017.1338270
Abstract: ABSTRACT Introduction: Blinatumomab is a T-cell engager antibody construct with dual specificity for CD19 and CD3, inducing serial lysis of CD19 positive B cells by redirecting cytotoxic T cells. It has been approved for the… read more here.
Keywords: cd19; cell engager; antibody construct; blinatumomab ... See more keywords
Ex silico engineering of cystine-dense peptides yielding a potent bispecific T cell engager
Sign Up to like & getrecommendations! Published in 2022 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abn0402
Abstract: Cystine-dense peptides (CDPs) are a miniprotein class that can drug difficult targets with high affinity and low immunogenicity. Tools for their design, however, are not as developed as those for small-molecule and antibody drugs. CDPs… read more here.
Keywords: cell engager; cdp; dense; cystine dense ... See more keywords
Abstract 2960: The novel trifunctional anti-BCMA NK cell engager SAR’514 has potent in-vitro, in-vivo and ex-vivo anti-myeloma effect through dual NK cell engagement
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2960
Abstract: Multiple Myeloma (MM) is the second most prevalent hematopoietic malignancy, representing 10% of total blood cancers. Despite the emergence of new therapies, it is still an incurable disease. Safe, potent and innovative approaches with long… read more here.
Keywords: cell engager; cell; vivo; sar 514 ... See more keywords
Visualizing Spatial and Stoichiometric Barriers to Bispecific T-cell Engager Efficacy.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer immunology research"
DOI: 10.1158/2326-6066.cir-21-0594
Abstract: Bispecific T-cell engager (BiTE) molecules are biologic T cell-directing immunotherapies. Blinatumomab is approved for treatment of B-cell malignancies, but BiTE molecule development in solid tumors has been more challenging. Here, we employed intravital imaging to… read more here.
Keywords: cell engager; cell; bite molecule; efficacy ... See more keywords
Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.tps2071
Abstract: TPS2071 Background: GBM is the most aggressive primary brain tumor in adults and is extremely difficult to treat. Patients with GBM tend to progress rapidly within weeks or months. Median overall survival is only 12–15… read more here.
Keywords: amg 596; cell engager; oncology; trial ... See more keywords